WINSUN BIO(BJ:839729)2023-08-07 16:00Financial Performance - The company's operating revenue for the first half of 2023 was CNY 152,714,720.89, a decrease of 1.80% compared to CNY 155,508,444.83 in the same period last year[24]. - The net profit attributable to shareholders of the listed company increased by 12.67% to CNY 39,790,645.55, up from CNY 35,315,527.79 in the previous year[24]. - The gross profit margin decreased to 62.11% from 64.67% year-on-year[24]. - The net cash flow from operating activities decreased by 74.77% to ¥5,195,970.28 compared to ¥20,595,869.57 in the same period last year[26]. - The total operating revenue for the first half of 2023 was CNY 152.71 million, a decrease of 1.80% compared to 155.51 million yuan in the previous year[42]. - Net profit for the period was 39.79 million yuan, an increase of 12.67% from 35.32 million yuan in the previous year, primarily due to increased government subsidies and reduced expenses[42]. - The total comprehensive income for the first half of 2023 was ¥39,779,039.89, compared to ¥35,301,271.67 in the same period last year, marking an increase of approximately 12.03%[126]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 817,351,722.55, down 5.93% from CNY 868,912,246.16 at the end of the previous year[25]. - Total liabilities decreased by 3.39% to CNY 166,911,702.00 from CNY 172,771,172.59 year-on-year[25]. - The net asset attributable to shareholders of the listed company was CNY 650,440,020.55, a decrease of 6.56% from CNY 696,141,073.57[25]. - The company's total assets decreased to CNY 817.31 million from CNY 868.88 million, indicating a reduction in asset base[119]. - Current liabilities totaled CNY 153.95 million, a slight decrease from CNY 157.86 million in the previous year[119]. Cash Flow and Investments - The net cash flow from investment activities was -506.36 million yuan, reflecting a 17.63% increase in outflow compared to -430.49 million yuan in the previous period[65]. - The net cash flow from financing activities was -515.69 million yuan, which is a 21.01% increase in outflow compared to -426.17 million yuan in the previous period[65]. - Cash and cash equivalents decreased by 32.97% to CNY 196.98 million from CNY 293.87 million due to cash dividend distribution and increased financial products[51]. - The company invested a total of 100.5 million yuan in financial products, with an expected balance of 200.5 million yuan remaining[68]. Research and Development - Research and development expenses totaled 12.36 million yuan, accounting for 8.10% of operating revenue, with several new veterinary drug registrations obtained during the period[43]. - The company holds 25 authorized patents, including 16 invention patents and 9 utility model patents, and has developed a new cell culture technology for vaccine production[31]. - The company has successfully developed a new type of classical swine fever vaccine using cell culture, which ranks among the top in market share for its core products[31]. Market and Sales - The poultry division achieved market sales revenue of 22.63 million yuan, a significant increase of 69.16% year-on-year[45]. - Export sales revenue reached 6.95 million yuan, reflecting a growth of 58.64% compared to the previous year[45]. - The company is actively expanding into international markets, currently working on product registrations in countries like Egypt[45]. Corporate Governance and Structure - The company has appointed two new independent directors, Zhang Jianfeng and Ren Tao, to the board[105]. - The total number of employees increased from 335 to 338, with a net addition of 3 employees during the reporting period[109]. - The company has no controlling shareholder or actual controller, and there are no related party relationships among the directors, supervisors, and senior management[102]. Compliance and Risk Management - The company is facing risks related to fluctuations in the livestock industry due to natural disasters and animal epidemics, which could impact vaccine demand[77]. - The company has implemented measures to ensure compliance with environmental regulations, including waste treatment and emissions monitoring[76]. - The company plans to diversify its product line and improve management to mitigate market risks associated with reliance on single products[77]. Shareholder Actions - The company completed a cash dividend distribution of CNY 75,581,106.72, distributing CNY 2.8 per 10 shares to all shareholders[4]. - The company plans to repurchase shares at a maximum price of 11.97 yuan per share, with a total repurchase amount estimated between 21.546 million and 43.092 million[87]. - As of June 30, 2023, the company has repurchased 3,574,800 shares, representing 1.31% of the total share capital, with a total expenditure of approximately 28.63 million yuan[88]. Financial Reporting and Accounting Policies - The company has maintained consistent accounting policies and estimates compared to the previous fiscal year, indicating stability in financial reporting[147]. - The company has not reported any significant changes in the scope of consolidated financial statements or related party transactions[147]. - The company's financial report for the first half of 2023 was approved by the board on August 7, 2023[156].